Compare · ADPT vs RVMD
ADPT vs RVMD
Side-by-side comparison of Adaptive Biotechnologies Corporation (ADPT) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ADPT and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $38.35B, about 11.0x ADPT ($3.50B).
- Over the past year, ADPT is up 112.1% and RVMD is up 369.1% - RVMD leads by 257.0 points.
- ADPT has been more active in the news (8 items in the past 4 weeks vs 3 for RVMD).
- RVMD has more recent analyst coverage (25 ratings vs 16 for ADPT).
- Company
- Adaptive Biotechnologies Corporation
- Revolution Medicines Inc.
- Price
- $21.87-4.58%
- $180.18-3.20%
- Market cap
- $3.50B
- $38.35B
- 1M return
- +30.18%
- +14.14%
- 1Y return
- +112.12%
- +369.10%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2020
- News (4w)
- 8
- 3
- Recent ratings
- 16
- 25
Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. It also has a research collaboration with Curebase, Inc. to enhance patient participation in clinical studies. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest ADPT
- Chief People Officer Lo Francis exercised 105,762 shares at a strike of $8.91 and sold $2,389,164 worth of shares (105,762 units at $22.59) as part of a pre-agreed trading plan (SEC Form 4)
- Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026
- Chief Scientific Officer Robins Harlan S sold $8,501,149 worth of shares (386,240 units at $22.01) as part of a pre-agreed trading plan, decreasing direct ownership by 27% to 1,019,658 units (SEC Form 4)
- Chief People Officer Lo Francis exercised 75,621 shares at a strike of $8.75 and sold $2,157,683 worth of shares (95,842 units at $22.51) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 230,713 units (SEC Form 4)
- Chief Commercial Officer, MRD Bobulsky Susan sold $10,714 worth of shares (487 units at $22.00) as part of a pre-agreed trading plan, decreasing direct ownership by 0.12% to 406,288 units (SEC Form 4)
- Chief Commercial Ofc Imm Med Benzeno Sharon exercised 114,329 shares at a strike of $7.75 and sold $3,503,510 worth of shares (165,802 units at $21.13) as part of a pre-agreed trading plan, decreasing direct ownership by 19% to 221,278 units (SEC Form 4)
- Chief Commercial Officer, MRD Bobulsky Susan sold $102,500 worth of shares (5,000 units at $20.50) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 406,775 units (SEC Form 4)
- Director Griffin Michelle Renee exercised 52,084 shares at a strike of $7.80 and sold $1,051,055 worth of shares (52,084 units at $20.18) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Adaptive Biotechnologies Corporation
- Adaptive Biotechnologies Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities
Latest RVMD
- European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process
- Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
- Director Patel Sushil exercised 2,955 shares at a strike of $37.54 and sold $1,048,967 worth of shares (5,580 units at $187.99) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 21,656 units (SEC Form 4)
- Chief Financial Officer Anders Jack exercised 20,000 shares at a strike of $18.56 and sold $3,366,604 worth of shares (20,000 units at $168.33) as part of a pre-agreed trading plan (SEC Form 4)
- Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
- Director Kim Lorence H. was granted 1,191 shares, increasing direct ownership by 2% to 74,281 units (SEC Form 4)
- Director Borisy Alexis was granted 1,191 shares, increasing direct ownership by 0.05% to 2,340,075 units (SEC Form 4)
- Director Anderson Elizabeth M was granted 1,191 shares, increasing direct ownership by 14% to 9,406 units (SEC Form 4)
- Director Horning Sandra was granted 1,191 shares, increasing direct ownership by 1% to 97,765 units (SEC Form 4)
- Director Clyburn Frank was granted 1,191 shares, increasing direct ownership by 12% to 10,929 units (SEC Form 4)